Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 8/20 | 0.40 |
| ▸ | ABCG2 | Q9UNQ0 | 7/20 | 0.40 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | MTTP | P55157 | 2/20 | 0.37 |
| ▸ | APOB | P04114 | 1/20 | 0.37 |
| ▸ | SMO | Q99835 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6498905 | 0.91 | ABCB1 (0.42) | ABCB1ABCG2ITGB3ITGA2BPRMT5 | |
| SCHEMBL6487457 | 0.90 | DRD2 (0.47) | ABCB1ABCG2ACACBTNFNOD1 | |
| SCHEMBL6489158 | 0.88 | SMO (0.46) | ABCB1ABCG2PRMT5WDR77MTTP | |
| SCHEMBL6489620 | 0.86 | ABCB1 (0.51) | ABCB1ABCG2TNFNOD1 | |
| SCHEMBL6491779 | 0.82 | ACACB (0.43) | ITGB3ITGA2BACACBMTTPAPOB | |
| SCHEMBL6501845 | 0.80 | NOD1 (0.47) | ACACBTNFNOD1 | |
| SCHEMBL6491162 | 0.78 | NOD1 (0.48) | ACACBTNFNOD1 | |
| SCHEMBL6490877 | 0.78 | MTTP (0.45) | ITGB3ITGA2BACACBTNFNOD1 | |
| SCHEMBL6491074 | 0.78 | PPARG (0.41) | ITGB3TNFNOD1MTTPAPOB | |
| SCHEMBL6489208 | 0.77 | NOD1 (0.41) | ITGB3ITGA2BACACBTNFNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | ABCB1 699/4885ABCG2 436/4885ITGB3 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.